Xian-Lian-Jie-Du Optimization Decoction as an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial.
Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in
the control group will be treated with placebo (XLJDOD mimetic agent).
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu Famous Medical Technology Co., Ltd.
Collaborator:
Jiangsu Province Hospital of Traditional Chinese Medicine